SY5-5 Real-world data in the era of immune checkpoint inhibitors

Abstract

Oesophageal cancer is the seventh most common cancer globally, and the sixth most common cause of death from cancer. The standard treatment for metastatic esophageal cancer after progression on for 1st line chemotherapy is nivolumab monotherapy in Japan. Survival benefit of nivolumab therapy occurred regardless of tumour PD-L1 expression in the ATTRACTION-3 trial. On the other hand, pembrolizumab was approved for metastatic, squamous cell carcinoma of the esophagus whose tumors express PD-L1 (Combined Positive Score [CPS] >10). Real world data after approval of nivolumab and pembrolizumab is not accumulated enough. Based on data of immune check inhibitors from clinical practice, it is warranted to discuss about the future treatment strategies of oesophageal cancer in the era of immune checkpoint inhibitors.